Triple negative breast cancer (tnbc) is an aggressive breast cancer subtype characterized with poor prognosis and high metastatic potential Current therapies like chemotherapy and radiation often harm both cancerous and. Tnbc exhibits high methylation rates, leading to the silencing of numerous tumor suppressor genes.
Ambjens on Twitter: "😘"
Tnbc patients with high ror1 expression are found to have poor prognosis and decreased overall survival rate compared to patients with low expression
Ror1 is thought to be a good drug target because it activates various oncogenic pathways such as pi3k/akt and stat3 in order to increase tnbc metastasis and chemoresistance.
We investigated the prevalence and prognostic significance of ror1 expression in triple negative breast cancer (tnbc). Ror1 is a promising drug target because it activates various oncogenic pathways such as pi3k/akt and stat3 in order to increase tnbc metastasis and chemoresistance1. Traditional chemotherapies are often toxic to normal cells Therefore, it is important to discover new anticancer compounds that target tnbc while.
Tnbc cells lack estrogen and progesterone receptors, and human epidermal growth factor receptor 2, which makes them resistant to standard hormone treatments
